Natalizumab treatment reduces fatigue in multiple sclerosis. Results from the TYNERGY trial; a study in the real life setting.
Fatigue is a significant symptom in multiple sclerosis (MS) patients. First-generation disease modifying therapies (DMTs) are at best moderately effective to improve fatigue. Observations from small cohorts have indicated that natalizumab, an antibody targeting VLA-4, may reduce MS-related fatigue....
Main Authors: | Anders Svenningsson, Eva Falk, Elisabeth G Celius, Siegrid Fuchs, Karen Schreiber, Sara Berkö, Jennifer Sun, Iris-Katharina Penner, Tynergy Trial Investigators |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3605436?pdf=render |
Similar Items
-
The Seasonal Fluctuation of Fatigue in Multiple Sclerosis
by: Matthias Grothe, et al.
Published: (2022-06-01) -
Editorial: Fatigue in multiple sclerosis—A current perspective
by: Anna Pokryszko-Dragan, et al.
Published: (2023-02-01) -
Natalizumab Induces Changes of Cerebrospinal Fluid Measures in Multiple Sclerosis
by: Ranjani Ganapathy Subramanian, et al.
Published: (2021-11-01) -
Natalizumab promotes anti-inflammatory and repair effects in multiple sclerosis.
by: Ragnhild Reehorst Lereim, et al.
Published: (2024-01-01) -
Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis
by: Ilaria Callegari, et al.
Published: (2023-01-01)